The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and chemotherapy in patients with pancreatic ductal adenocarcinoma.
At a 3.2-year median follow up, the eight patients who had developed T cell responses from the vaccine had not reached their median recurrence-free survival. In comparison, the eight patients who did not develop the immune responses saw their cancer return after a median of 13.4 months. The vaccine-induced CD8+ T cells that help fight cancer were found to have long lifespans, with some remaining active three years following vaccination.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
